• Price (EUR)0.1055
  • Today's Change0.00 / 0.00%
  • Shares traded0.00
  • 1 Year change-97.28%
  • Beta1.1555
Data delayed at least 15 minutes, as of Aug 15 2022 08:47 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

Magforce AG is a Germany-based company engaged in the provision of nanotechnology solutions for health sector. Its non-invasive technology uses magnetic nanoparticles to combat tumors, without harmful effect on the healthy tissues. The Company's range of treatment products includes NanoTherm Therapie for treating tumors locally; NanoTherm, a fluid containing ferrous oxide molecules that penetrate deeply into the tumor tissues and reacting to the presence of a magnetic field; NanoActivator, which are iron oxide nanoparticles for tumors in all areas of the body, and NanoPlan, a software platform that facilitates therapy planning and adjusts proper temperatures for the treatment and and the necessary magnetic field strength. As of December 31, 2011, Nanostart AG held a 49.6%-stake in the Company.

  • Revenue in EUR (TTM)351.98k
  • Net income in EUR-10.57m
  • Incorporated2005
  • Employees69.00
  • Location
    Magforce AGMax-Planck-Strasse 3BERLIN 12489GermanyDEU
  • Phone+49 303083800
  • Fax+49 3 030838099
  • Websitehttps://www.magforce.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Fritz Nols AG486.38k-65.09k1.10m5.00------3.11-0.0109-0.01090.0591-----------------------18.37----------43.16--135.13------
AFKEM AG656.00k148.00k1.39m4.007.681.628.622.120.24080.24081.071.14----------0.7245--0.793594.6633.9922.711.12----0.000.00-46.97-21.07513.04-8.48----
Readcrest Capital AG0.00-134.85k1.41m0.00---------0.0450-0.04530.00-0.0290.00-------107.54-48.51-202.02-56.09--------------------23.46------
Jost AG-100.00bn-100.00bn2.63m7.00--------------------------17.05--19.53------12.31---------5.5310.686.4628.65----
MagForce AG351.98k-10.57m3.59m69.00--0.1232--10.12-0.3531-0.35310.01180.89670.00553.470.85325,101.16-16.47-3.78-31.53-6.78-89.9525.30-3,004.22-295.230.0321-1.970.2485---43.33-5.77-171.71------
Centurion International AG-100.00bn-100.00bn3.70m--------------------------------------------------608.97--17,191.89------
MBH Corporation PLC129.13m3.56m8.85m0.002.350.11931.270.06890.04620.00251.670.90820.752418.798.42--2.07--2.61--23.30--2.76--0.92772.400.4042--94.02--167.59------
Plenum AG17.31m508.42k9.85m75.0019.362.359.760.56420.29950.299510.192.461.11127.364.06--3.254.324.185.4586.7386.362.942.981.87--0.34880.00-5.4415.89-35.46------
Palgon AG0.0016.35k12.00m--733.8171.48----0.05450.05450.000.55960.00------9.59--9.77--------------0.00------117.47------
CytoTools AG44.63k-4.06m17.47m0.00--0.792--392.54-0.9782-0.97820.01084.310.0022--0.4238---20.01-11.61-20.19-12.35-----9,094.60-4,674.96---0.61410.00--23.97---120.69------
Data as of Aug 15 2022. Currency figures normalised to Magforce AG's reporting currency: Euro EUR
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.